Health and illness beliefs in adults with tuberculosis infection during the COVID-19 pandemic in the UK.

Autor:	Kılıç A; School of Pharmacy, University College London, London, UK., Clarke AL; School of Pharmacy, University College London, London, UK., Moon Z; School of Pharmacy, University College London, London, UK., Hamada Y; Institute for Global Health, University College London, London, UK., Chan AHY; School of Pharmacy, University of Auckland, Auckland, New Zealand., Rahman A; Department of Respiratory Medicine, Barts Health NHS Trust, London, UK., Layton C; MRC Clinical Trials Unit, University College London, UK., Griffiths CJ; Centre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK., Zenner D; Centre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK., Powell E; MRC Clinical Trials Unit, University College London, UK., Kunst H; Respiratory Medicine, Queen Mary University of London, London, UK., Lipman M; Royal Free London NHS Foundation Trust, London, UK.; UCL-TB and UCL Respiratory, University College London, London, UK., Mandelbaum M; TB Alert, Brighton, UK., Papineni P; London Northwest University Healthcare NHS Trust, London, UK., Tattersall T; MRC Clinical Trials Unit, University College London, UK., Duong T; MRC Clinical Trials Unit, University College London, UK., Abubakar I; Institute for Global Health, University College London, London, UK., Rangaka MX; Institute for Global Health, University College London, London, UK.; Division of Epidemiology and Biostatistics & CIDRI-AFRICA, University of Cape Town, Cape Town, South Africa., Horne R; School of Pharmacy, University College London, London, UK.
Jazyk:	angličtina
Zdroj:	Dialogues in health [Dialogues Health] 2023 Nov 29; Vol. 4, pp. 100162. Date of Electronic Publication: 2023 Nov 29 (Print Publication: 2024).
DOI:	10.1016/j.dialog.2023.100162
Abstrakt:	Background: COVID-19 disrupted the TB prevention programme in the UK, especially for TB infection (TBI) care. We explore whether experience of the COVID-19 pandemic impacted on patients' perceptions of TBI and its treatment. Methods: Semi-structured interviews were conducted as part of the Research to Improve Detection and Treatment of TBI (RID-TB) programme, exploring perceptual and practical barriers to TBI treatment. Nineteen people diagnosed with TBI were interviewed between August 2020 and April 2021. Recordings were transcribed and analysed using a constant comparative approach, allowing for a dynamic and iterative exploration of themes. Themes are organised using the Perceptions and Practicalities Approach. Findings: Some participants perceived TBI as a risk factor for increased susceptibility to COVID-19, while some thought that treatment for TBI might protect against COVID-19 or mitigate its effects. Adaptations to TB services (e.g., remote follow-up) and integrated practices during the COVID-19 restrictions (e.g., medication being posted) addressed some practical barriers to TBI treatment. However, we identified beliefs about TBI and COVID-19 that are likely to act as barriers to engagement with TBI treatment, including: interpreting service delays as an indication of TBI not being serious enough for treatment and concerns about contracting COVID-19 in TB clinics. Interpretation: COVID-19 and TBI service delays influence people's perceptions and practical barriers to TBI treatment adherence. Failure to address these beliefs may lead to people's concerns about their treatment not being fully addressed. Utilised service adaptations like remote consultations to address practical barriers may be relevant beyond COVID-19. Funding: NIHR RID-TB Program (RP-PG-0217-20009). Competing Interests: None. (© 2023 Published by Elsevier Inc. CC BY-NC-ND 4.0.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu